NEW YORK, June 22 (GenomeWeb News) - Miraculins, a Winnipeg, Manitoba-based proteomics shop, has acquired the IP portfolio of Europroteome, a German molecular diagnostics company that filed for bankruptcy late last year, the company said.
According to Miraculins, the portfolio includes 14 patents and numerous discoveries related to the diagnosis of several cancers. The company said Miraculins has no further milestone or royalty commitments related to the patents. Miraculins said it plans to capitalize on the acquisition of the various biomarkers by developing assays to run on its mass spectrometry-based BEST platform. The company recently announced the completion of a prostate cancer diagnostic-discovery study.
Miraculins also announced that it has granted an aggregate of 25,000 stock options at an exercise price of $2.20 per common share to certain officers and directors in the company. The options are set to expire five years from date of grant and are subject to approval of the TSX Venture Exchange.